Evidence map›Paper›PMID 33717068›Full record

ArticleFrontiers in immunology2021

Targeting miR-148b-5p Inhibits Immunity Microenvironment and Gastric Cancer Progression.

Yuyu Zhang, Wei Huo, Lidi Sun, Jie Wu, Chengbin Zhang, Huanhuan Wang, Bin Wang, Jinlong Wei, Chao Qu, Hongshi Cao and 1 more

Abstract read
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Annals of translational medicine · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Yuyu ZhangDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Wei HuoDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Lidi SunDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Jie WuDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Chengbin ZhangDepartment of Pathology Oncology, The First Hospital of Jilin University, Changchun, China.
Huanhuan WangDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Bin WangDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Jinlong WeiDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Chao QuDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.
Hongshi CaoDepartment of Nursing, The First Hospital of Jilin University, Changchun, China.
Xin JiangDepartment of Radiation Oncology, The First Hospital of Jilin University, Changchun, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: MicroRNAs (miRNAs) have been discovered to dictate the development of various tumors. However, studies on the roles of miRNAs in the progression of gastric cancer (GC) are still lacking. Methods: Herein, by analyzing GC cell lines and patients samples, we observed that miR-148b-5p was significantly downregulated in GC. We also confirmed that miR-148b-5p overexpression significantly inhibited GC cell proliferation and invasion Results: Overexpression of miR-148b-5p not only reprogrammed the metabolic properties of GC but also regulated the immune microenvironment by shifting lymphocyte and myeloid populations. Mechanistically, ATPIF1, an important glycolysis-associated gene, was identified as a direct target of miR-148b-5p and mediated the effect of miR-148b-5p. Notably, the low level of miR-148b-5p was significantly related with poor prognosis of GC patients ( Conclusions: Targeting miR-148b-5p inhibits immunity microenvironment and gastric cancer progression.

Indexed as

AnimalsBiomarkers, TumorCell Line, TumorDisease Models, AnimalDisease ProgressionGene Expression Regulation, NeoplasticGene TargetingHeterograftsHumansMiceMicroRNAsPrognosisStomach NeoplasmsTumor MicroenvironmentBiomarkers, TumorMicroRNAsMIRN148 microRNA, humanATPIF1gastric cancerimmune microenvironmentmetabolic reprogrammingmiR-148b-5p

Identifiers

PMID33717068
PMCPMC7944991

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.